Uppsala
18-65 years
Healthy individualsStudy 894
We are looking for healthy participants for a study involving an investigational drug for drug-resistant epilepsy (DRE).
The purpose of the study is to investigate the drug’s safety and tolerability, as well as how it is absorbed
, distributed, and excreted in the body following repeated dosing over a two-week period in healthy
individuals.
Target group: healthy individuals, ages 18–65
Criteria for participation:
- Be healthy
- Have a BMI between 18.5 and 30 kg/m²
- Weigh at least 55 kg
- Do not use nicotine or tobacco products on a regular basis
- Do not take any medications or dietary supplements
- Have not participated in any other drug trial in the past three months
- Have not donated blood in the past three months (or plasma in the past month)
- Be willing to use a dual barrier method during heterosexual intercourse. This means that
both the man and the woman need to use approved contraceptives or be
sterile or postmenopausal. - Women must not be pregnant, planning to become pregnant, or breastfeeding during the study
The study consists of four visits to our clinic in Uppsala: one health checkup, two clinic visits, and one
follow-up visit. During one of these visits, you will stay at the clinic and spend 16 days there.
You will receive the study medication or a placebo in capsule form once a day for 14 days.
A lumbar puncture will be performed on two occasions. This is a common medical
procedure in which a sample of cerebrospinal fluid is taken from the lower back under local anesthesia by
experienced healthcare professionals.
Compensation: 56,140 SEK for your participation.
Schedule
| GROUP (Cohort 1) | Health check-up (visit 1) | Additional Visit | Inpatient stay at the clinic (visit 2) | Follow-up visit (Visit 3) |
| Group 1 | August 17 or 19 | Sept. 1 | September 7–23 | October 5 |
| Group 2 | August 17 or 19 | Sept. 1 | September 8–24 | October 6 |
| Group 3 | August 17 or 19 | Sept. 1 | September 9–25 | October 7 |
More information and registration
Would you like to participate in the study?Please submit an expression of interest using the form below.
Do you have any questions or want to know more?Call 018-30 33 99 or emailinfo@ctc-ab.se.
The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).
